Evidence map›Paper›PMID 33107485›Full record

ArticleThe Indian journal of medical research2020

Evaluation of multiparametric flow cytometry in diagnosis & prognosis of myelodysplastic syndrome in India.

Gaurav Dhingra, Jasmita Dass, Vandana Arya, Nitin Gupta, Amrita Saraf, Sabina Langer, Shyam Aggarwal, Jyoti Kotwal, Manorama Bhargava

Open access · diamondAbstract read
In one paragraph

Article in The Indian journal of medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Gaurav DhingraDepartment of Hematology, Sir Ganga Ram Hospital, New Delhi, India.
Jasmita DassDepartment of Hematology, Sir Ganga Ram Hospital, New Delhi, India.
Vandana AryaDepartment of Hematology, Sir Ganga Ram Hospital, New Delhi, India.
Nitin GuptaDepartment of Clinical Hematology, Sir Ganga Ram Hospital, New Delhi, India.
Amrita SarafDepartment of Hematology, Sir Ganga Ram Hospital, New Delhi, India.
Sabina LangerDepartment of Hematology, Sir Ganga Ram Hospital, New Delhi, India.
Shyam AggarwalDepartment of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India.
Jyoti KotwalDepartment of Hematology, Sir Ganga Ram Hospital, New Delhi, India.
Manorama BhargavaDepartment of Hematology, Sir Ganga Ram Hospital, New Delhi, India.
Sir Ganga Ram Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & objectives: Diagnosis of myelodysplastic syndromes (MDS) is subjective in low-grade cases with <5 per cent blasts or <15 per cent ring sideroblasts. Flow cytometry (FCM) has been used to diagnose MDS; but, it still has only an adjunctive role. This study was conducted to evaluate the role of FCM to diagnose MDS and correlate the number of aberrancies with revised international prognostic scoring system (R-IPSS). Methods: This study included 44 consecutive clinically suspected cases of MDS with refractory cytopenia(s) and 10 controls. Patients were divided into two groups: (i) proven MDS cases (n=26), and (ii) suspected MDS (n=18). Ogata quantitative approach, pattern analysis and aberrant antigen expression were studied. Results: Ogata score ≥2 correctly diagnosed 80.7 per cent (21/26) while aberrant antigen and pattern analysis with flow score of ≥3 could diagnose 92.3 per cent (24/26) patients with proven MDS. Combination of both with flow score ≥3 could diagnose 100 per cent patients. Eight patients in suspected MDS group with persistent cytopenia on follow up were labelled as probable MDS. Ogata score ≥2 was present in 5 of 8 and pattern analysis score ≥3 was present in six probable MDS patients. Combination of both with flow score ≥3 was present in seven of eight patients. Spearman's correlation between Ogata score and R-IPSS, pattern analysis and R-IPSS and combination of both scores and R-IPSS showed significant positive correlation in proven MDS as well as when proven and probable MDS patients were combined. Interpretation & conclusions: Our results showed that combined Ogata approach and pattern analysis, demonstration of ≥3 aberrancies in >1 cell compartment could diagnose most MDS patients. Patients with high flow scores had high R-IPSS scores. Patient with flow score ≥3 and borderline cytomorphology should be observed closely for the development of MDS.

Indexed as

Myelodysplastic SyndromesFlow CytometryHumansImmunophenotypingIndiaPrognosisELN guidelineflow cytometryflow scoremyelodysplastic syndromesOgata scorering sideroblasts

Identifiers

PMID33107485
PMCPMC7881827
OpenAlexW3093445829

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.